Keyphrases
High-throughput
100%
E3 Ligase Activity
100%
Matrix-assisted Laser Desorption Ionization-time of Flight Mass Spectrometry (MALDI-TOF MS)
100%
Parkin
100%
Parkinson's Disease
33%
In Vitro Activity
33%
Treatment Strategy
16%
Gain-of-function mutation
16%
E3 Ubiquitin Ligase
16%
Small Molecules
16%
Accurate Quantification
16%
Pharmacological Treatment
16%
Therapeutic Approaches
16%
Primary Screening
16%
Patients with Parkinson's Disease
16%
Non-motor Symptoms
16%
Autonomic Abnormalities
16%
Progressive Neurological Disease
16%
Complementary Matrices
16%
High-throughput Platform
16%
Neuroscience
Ligase
100%
Mass Spectrometry
100%
Parkin
100%
Parkinson's Disease
50%
In Vitro
33%
Ubiquitin Protein Ligase E3
16%
Nervous System Disorder
16%
Loss of Function Mutation
16%
Non-Motor Symptoms
16%
Drug Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ligase
100%
Matrix-Assisted Laser Desorption/Ionization
100%
Parkin
100%
Parkinson's Disease
50%
Neurologic Disease
16%
Ubiquitin Protein Ligase E3
16%